Evidence map›Paper›PMID 37456028›Full record

ArticleHeliyon2023

Triethylammonium salt of a synthesized dicoumarol: Structural insight and human anti-glioblastoma activities.

Afzal Khan, Muhammad Ikram, Sadia Rehman, Rizwan Khan, Vinay K Puduvalli, Ayub Jadoon, Momin Khan, Fawaz Alasmari, Abdullah F AlAsmari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Afzal KhanDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Muhammad IkramDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Sadia RehmanDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Rizwan KhanDepartment of Zoology, Abdul Wali Khan University, Mardan, Pakistan.
Vinay K PuduvalliDepartment of Zoology, Abdul Wali Khan University, Mardan, Pakistan.
Ayub JadoonDepartment of Microbiology, Abbotabad University of Science and Technology, Abbotabad, Pakistan.
Momin KhanDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Fawaz AlasmariDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdullah F AlAsmariDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common and primary brain tumor with poor prognosis. They are removed by following tedious and life threatening surgeries. GBM stem cells (GSCs) are the main source of tumor recurrence after surgery. Hence, drugs are designed to overcome the recurrent glioblastoma malignant cells. Currently used chemotherapies are not cost effective as well as bear resistance. New and effective chemotherapeutic compounds are developed to overcome the intrinsic and acquired resistance. Dicoumarol derivative 3,3'-[(4-methoxyphenyl)methanediyl]bis(4-hydroxy-2Hchromen-2-one) (HL) and its triethylammonium salt triethylammonium3-[(4-methoxyphenyl)(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]-2-oxo-2H-chromen-4-olate (L) were synthesized and characterized using spectral and analytical techniques. The deprotonated compound L was further studied structurally using single crystal analysis. Cytotoxic studies against human glioblastoma cells A172 and LN229 were investigated both dose and time dependently and compared with the cytotoxicity of normal human astrocytes (NHA). The IC

Indexed as

DicoumarolDicoumarol triethylammonium saltFlow cytometryFree radical scavengingGlioblastomaPhase contrast microscopy

Identifiers

PMID37456028
PMCPMC10338367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.